Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1986 2
1987 1
1988 3
1991 5
1994 2
1995 3
1996 9
1997 5
1998 5
1999 12
2000 12
2001 5
2002 6
2003 7
2004 6
2005 7
2006 11
2007 11
2008 11
2009 13
2010 8
2011 17
2012 11
2013 18
2014 19
2015 24
2016 29
2017 19
2018 21
2019 27
2020 33
2021 18
2022 23
2023 21
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

390 results

Results by year

Filters applied: . Clear all
Page 1
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P=0.0 …
The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo gro …
Guideline for management of septic arthritis in native joints (SANJO).
Ravn C, Neyt J, Benito N, Abreu MA, Achermann Y, Bozhkova S, Coorevits L, Ferrari MC, Gammelsrud KW, Gerlach UJ, Giannitsioti E, Gottliebsen M, Jørgensen NP, Madjarevic T, Marais L, Menon A, Moojen DJ, Pääkkönen M, Pokorn M, Pérez-Prieto D, Renz N, Saavedra-Lozano J, Sabater-Martos M, Sendi P, Tevell S, Vogely C, Soriano A, The Sanjo Guideline Group. Ravn C, et al. J Bone Jt Infect. 2023 Jan 12;8(1):29-37. doi: 10.5194/jbji-8-29-2023. eCollection 2023. J Bone Jt Infect. 2023. PMID: 36756304 Free PMC article.
Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU.
Krag M, Marker S, Perner A, Wetterslev J, Wise MP, Schefold JC, Keus F, Guttormsen AB, Bendel S, Borthwick M, Lange T, Rasmussen BS, Siegemund M, Bundgaard H, Elkmann T, Jensen JV, Nielsen RD, Liboriussen L, Bestle MH, Elkjær JM, Palmqvist DF, Bäcklund M, Laake JH, Bådstøløkken PM, Grönlund J, Breum O, Walli A, Winding R, Iversen S, Jarnvig IL, White JO, Brand B, Madsen MB, Quist L, Thornberg KJ, Møller A, Wiis J, Granholm A, Anthon CT, Meyhoff TS, Hjortrup PB, Aagaard SR, Andreasen JB, Sørensen CA, Haure P, Hauge J, Hollinger A, Scheuzger J, Tuchscherer D, Vuilliomenet T, Takala J, Jakob SM, Vang ML, Pælestik KB, Andersen KLD, van der Horst ICC, Dieperink W, Fjølner J, Kjer CKW, Sølling C, Sølling CG, Karttunen J, Morgan MPG, Sjøbø B, Engstrøm J, Agerholm-Larsen B, Møller MH; SUP-ICU trial group. Krag M, et al. N Engl J Med. 2018 Dec 6;379(23):2199-2208. doi: 10.1056/NEJMoa1714919. Epub 2018 Oct 24. N Engl J Med. 2018. PMID: 30354950 Clinical Trial.
At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI], 0.91 to 1.13; P=0.76). During the ICU stay, at least one clinically important event (a composite of clinically impor …
At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidenc …
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persist …
The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; h …
Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
Møller JE, Engstrøm T, Jensen LO, Eiskjær H, Mangner N, Polzin A, Schulze PC, Skurk C, Nordbeck P, Clemmensen P, Panoulas V, Zimmer S, Schäfer A, Werner N, Frydland M, Holmvang L, Kjærgaard J, Sørensen R, Lønborg J, Lindholm MG, Udesen NLJ, Junker A, Schmidt H, Terkelsen CJ, Christensen S, Christiansen EH, Linke A, Woitek FJ, Westenfeld R, Möbius-Winkler S, Wachtell K, Ravn HB, Lassen JF, Boesgaard S, Gerke O, Hassager C; DanGer Shock Investigators. Møller JE, et al. N Engl J Med. 2024 Apr 18;390(15):1382-1393. doi: 10.1056/NEJMoa2312572. Epub 2024 Apr 7. N Engl J Med. 2024. PMID: 38587239 Clinical Trial.
Death from any cause occurred in 82 of 179 patients (45.8%) in the microaxial-flow-pump group and in 103 of 176 patients (58.5%) in the standard-care group (hazard ratio, 0.74; 95% confidence interval [CI], 0.55 to 0.99; P = 0.04). A composite safety end-point event occurr …
Death from any cause occurred in 82 of 179 patients (45.8%) in the microaxial-flow-pump group and in 103 of 176 patients (58.5%) in the stan …
Blood Pressure and Oxygen Targets on Kidney Injury After Cardiac Arrest.
Rasmussen SB, Jeppesen KK, Kjaergaard J, Hassager C, Schmidt H, Mølstrøm S, Beske RP, Grand J, Ravn HB, Winther-Jensen M, Meyer MAS, Møller JE. Rasmussen SB, et al. Circulation. 2023 Dec 5;148(23):1860-1869. doi: 10.1161/CIRCULATIONAHA.123.066012. Epub 2023 Oct 4. Circulation. 2023. PMID: 37791480 Clinical Trial.
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.
Seckinger A, Majocchi S, Moine V, Nouveau L, Ngoc H, Daubeuf B, Ravn U, Pleche N, Calloud S, Broyer L, Cons L, Lesnier A, Chatel L, Papaioannou A, Salgado-Pires S, Krämer S, Gockel I, Lordick F, Masternak K, Poitevin Y, Magistrelli G, Malinge P, Shang L, Kallendrusch S, Strein K, Hose D. Seckinger A, et al. J Hematol Oncol. 2023 Dec 12;16(1):117. doi: 10.1186/s13045-023-01516-3. J Hematol Oncol. 2023. PMID: 38087365 Free PMC article.
Characterization of Familial and Sporadic Migraine.
Ravn J, Chalmer MA, Oehrstroem EL, Kogelman LJA, Hansen TF. Ravn J, et al. Headache. 2019 Nov;59(10):1802-1807. doi: 10.1111/head.13640. Epub 2019 Sep 22. Headache. 2019. PMID: 31544229 Free PMC article.
RESULTS: No differences in age (Mean = 44 and 44 [SD = 12.28 and 12.58] for familial and sporadic migraineurs, respectively; P = .900) or sex (295/358 (82.4%) and 1413/1727 (81.8%) women in familial and sporadic migraineurs, respectively; P = .853) were found. Famil …
RESULTS: No differences in age (Mean = 44 and 44 [SD = 12.28 and 12.58] for familial and sporadic migraineurs, respectively; P = .900 …
Skin TARC/CCL17 increase precedes the development of childhood atopic dermatitis.
Halling AS, Rinnov MR, Ruge IF, Gerner T, Ravn NH, Knudgaard MH, Trautner S, Loft N, Skov L, Thomsen SF, Egeberg A, Guttman-Yassky E, Rosted ALL, Petersen T, Jakasa I, Kezic S, Thyssen JP. Halling AS, et al. J Allergy Clin Immunol. 2023 Jun;151(6):1550-1557.e6. doi: 10.1016/j.jaci.2022.11.023. Epub 2022 Dec 23. J Allergy Clin Immunol. 2023. PMID: 36572354 Free article.
Elevated thymus- and activation-regulated chemokine/C-C motif chemokine ligand 17 -levels collected at 2 months of age increased the overall risk of AD (HR: 2.11; 95% CI: 1.36-3.26; P = .0008) and moderate-to-severe AD (HR: 4.97; 95% CI: 2.09-11.80; P = .0003). ...L …
Elevated thymus- and activation-regulated chemokine/C-C motif chemokine ligand 17 -levels collected at 2 months of age increased the overall …
Ruptured popliteal artery aneurysm.
Cervin A, Ravn H, Björck M. Cervin A, et al. Br J Surg. 2018 Dec;105(13):1753-1758. doi: 10.1002/bjs.10953. Epub 2018 Jul 24. Br J Surg. 2018. PMID: 30043540 Free PMC article.

Patients with rPAA were 8 years older (77.7 versus 69.7 years; P < 0.001), had more lung and heart disease (P = 0.003 and P = 0.019 respectively), and a larger mean popliteal aneurysm diameter (63.7 versus 30.9 mm; P < 0.001) than patients with P

…

Patients with rPAA were 8 years older (77.7 versus 69.7 years; P < 0.001), had more lung and heart disease (P = 0.003 and

…
390 results